Population Pharmacokinetics and Pharmacodynamics of Ciprofol
NCT ID: NCT07301242
Last Updated: 2025-12-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
50 participants
OBSERVATIONAL
2025-10-28
2026-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The main question it aims to answer is: Does ciprofol work safely and effectively in older adults during orthopedic surgery?
Participants already receiving ciprofol as part of their regular anesthesia care will:
1. Provide blood samples at different time points during and after surgery.
2. Have their vital signs and anesthesia-related data recorded before, during, and after surgery.
3. Be monitored for side effects and recovery indicators such as the Aldrete score and signs of postoperative delirium.
Researchers will use this information to:
1. Build and test a population PK/PD model for ciprofol.
2. Simulate recommended TCI dosing plans.
3. Explore how individual responses to ciprofol relate to recovery and safety outcomes.
This study may help improve anesthesia care for elder adults by making drug dosing safer and more effective.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Ciprofol, a novel intravenous anesthetic, has shown promising efficacy and safety in clinical practice. However, existing PK/PD models are largely derived from healthy volunteers or younger patients, and cannot adequately predict drug behavior in elderly orthopedic patients who often present with comorbidities and heightened surgical stress. This gap may lead to risks such as drug accumulation and circulatory depression, or insufficient dosing and intraoperative awareness.
This single-center, observational, prospective study at Shanghai Geriatric Medical Center aims to construct and validate a population PK/PD model of ciprofol specifically for elderly patients undergoing orthopedic limb surgery. The model will support precise control of effect-site concentration via Target-Controlled Infusion (TCI) systems, enabling individualized anesthesia management.
Study Objectives 1.Primary Objective: To develop and validate a population PK/PD model of ciprofol tailored to elderly orthopedic patients, and to evaluate its accuracy in predicting effect-site concentrations.
2.Secondary Objectives:
1. To simulate recommended TCI dosing regimens based on the new model and compare them with current drug label recommendations, assessing clinical value and optimization potential.
2. To evaluate the anesthetic efficacy and safety of ciprofol in this patient population.
3.Exploratory Objectives: To investigate the influence of covariates (e.g., age, sex, BMI, hepatic and renal function) on PK/PD parameters, and to explore correlations between individual PK/PD parameters and recovery outcomes such as Aldrete score and postoperative delirium incidence.
Study Design
1.Type: Single-center, observational, biosample-utilization study. 2.Population: 45 elderly patients (≥65 years, ASA I-III) scheduled for elective orthopedic limb surgery under general anesthesia.
3.Procedures:
1. Collection of perioperative clinical data (vital signs, BIS monitoring, anesthesia-related indicators).
2. Serial blood sampling at predefined time points for plasma concentration measurement.
3. Monitoring of anesthetic efficacy (induction success, BIS values, recovery times) and safety endpoints (hypotension, bradycardia, hypoxemia, injection pain).
4.Endpoints:
1. Primary Endpoint: Accuracy of the population PK/PD model in predicting effect-site concentrations.
2. Secondary Endpoints: Differences between model-recommended dosing and label-based dosing; incidence of ciprofol-related adverse events; anesthetic efficacy indicators.
3. Exploratory Endpoints: Covariate effects on PK/PD parameters; correlation of PK/PD parameters with Aldrete score recovery and postoperative delirium.
Data Management and Analysis All perioperative data will be recorded and stored electronically, with double-entry verification and query resolution procedures to ensure accuracy. PK/PD modeling will be performed using nonlinear mixed-effects modeling (NONMEM). Model evaluation will include goodness-of-fit plots, visual predictive checks, and bootstrap validation. Simulations will be conducted to compare TCI dosing regimens derived from the new model with standard recommendations.
Expected Significance This study will fill an important gap in anesthetic pharmacology by providing a validated PK/PD model of ciprofol for elderly orthopedic patients. The findings are expected to improve perioperative anesthesia management, enhance patient safety, and support individualized dosing strategies in clinical practice.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Elderly Orthopedic Limb Surgery Cohort
Inclusion Criteria:
Age ≥65 years; BMI 18-30 kg/m²; ASA physical status classification I-III; Scheduled for elective orthopedic limb surgery under general anesthesia; Expected duration of surgery \>30 minutes; Willing to participate and able to provide written informed consent.
Exclusion Criteria:
Known allergy to ciprofol or related medications, or any contraindication to their use; Preoperative cognitive impairment (Mini-Cog score \<3); History of severe cerebrovascular disease or related complications; History of neuromuscular system diseases or psychiatric disorders; History of sedative medication use; History of alcohol abuse or substance use disorder; Bradycardia (heart rate \<60 beats per minute); Hypotension (mean arterial pressure \<55 mmHg); QT interval prolongation; Uncooperative or unable to communicate effectively.
Ciprofol
Ciprofol is used as an intravenous anesthetic agent for sedation and anesthesia induction/maintenance in elderly patients undergoing elective orthopedic limb surgery. In this observational study, ciprofol is administered according to standard clinical practices, and data on its pharmacokinetics, pharmacodynamics, safety, and effectiveness in this specific population will be collected.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Ciprofol
Ciprofol is used as an intravenous anesthetic agent for sedation and anesthesia induction/maintenance in elderly patients undergoing elective orthopedic limb surgery. In this observational study, ciprofol is administered according to standard clinical practices, and data on its pharmacokinetics, pharmacodynamics, safety, and effectiveness in this specific population will be collected.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* BMI: 18-30 kg/m²;
* ASA physical status classification I-III;
* Scheduled for elective orthopedic limb surgery under general anesthesia;
* Expected duration of surgery \>30 minutes;
* Willing to participate and able to provide written informed consent.
Exclusion Criteria
* Preoperative cognitive impairment;
* History of severe cerebrovascular disease or related complications;
* History of neuromuscular system diseases or psychiatric disorders;
* History of sedative medication use;
* History of alcohol abuse or substance use disorder;
* Bradycardia (heart rate \<60 beats per minute);
* Hypotension (mean arterial pressure \<55 mmHg);
* QT interval prolongation;
* Uncooperative or unable to communicate effectively.
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Shanghai Geriatric Medical Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Xue Zhang
Attending Physician
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Xue Zhang
Role: PRINCIPAL_INVESTIGATOR
Shanghai Geriatric Medical Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Shanghai Geriatric Medical Center
Shanghai, , China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Clinical Research Coordinator
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ZCLY2025-021
Identifier Type: -
Identifier Source: org_study_id